ReviewCancers2021

Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options.

Constanze Elfgen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.